VOLUME 58, NUMBER 7
`
`PUBLISHED MONTHLY
`
`JULY 2014
`
`Antimicrobial agents and chemotherapy.
`v. 58. rm. T {July 2014)
`Genera Collection
`W1 AMEM
`
`ROBlAL
`AGETS AND
`CHEMOTHERAPY
`
`aNTmIca HT HH HnURaP' "
`
`2914 VOLUME 58 ISSUE 7
`
`
`
`immLilliiuii
`a.17724646 5i
` “La—Lou
`
`33E INDEXED
`03 3975517
`
`,1!
`
`u
`
`Page 1 0f17
`
`Acrux V. Kaken
`
`IPR2017-0019O
`
`Kaken Exhibit 2049
`
`

`

`VVIBATn/i
`®
`[telavancinlforinjection
`
`\rlElA't'Ilr‘t [telavancinl for injection. for intravenous use
`RX ONLY
`
`BRIEF SUMMARY. See package insert available at vnvw.vibativ.com lortull Prescribing
`Information. including Boxed Warning and Medication Guide.
`
`INDICATIONS AND USAGE: VIBATIV is a lipoglycopeotlde antibacterial drug indicated for the
`treatment of the following infections in adult patients caused by designated susceptible bacle ha:
`- Complicated skin and skin structure infections [c8850
`-
`hospital-acquired and ventilator-associated bacterial pneumonia (HABPNABP) caused by
`susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when
`alternative treatments are not suitable.
`
`CONTRAINDICATIONS: VlBATW is contraindicated In patients with known hypersensitivity to
`lelavancin.
`
`WARNINGS: Patients with pro-existing moderatefsevere renal impairment {CrCI
`£50 mUminl who were treated with VlEiATIV for hospital-acquired bacterial pneumonia.r
`ventilator-associated bacterial pneumonia had increased mortality observed versus
`vancomycin. Use of \l'lBrlTllir
`in patients with pro-existing moderato'severe renal
`impairment (CrCI 550 mLfminl should be considered onlywhen the anticipated benefit
`to the patient outweighs the potential risk.
`Nephrotoxicity: New onset or worsening renal impairment has occurred. Monitor
`renal function in all patients.
`Women of childbearing potential should have a serum pregnancy test prior to
`administration of VIBATIV. Avoid use of VlBA‘fN during pregnancy unless potential
`benefit to the patient outweighs potential risk to the fetus. Adverse developmental
`outcomes observed in 3 animal species at clinically relevant doses raise concerns
`
`about potential adverse deveIOpmental outcomes in humans.
`
`be instituted as clinically indicated. Development of Drug-Resistant Bacteria: Prescribing
`VIBATIV in the absence of a proven or strongly suspected bacterial infection is unlikely to
`provide benefit to the patient and increases the risk of the development of drug-resistant
`bacteria As with other antibacterial drugs. use of \flElhTIi.r may result in overgrowth of
`nonsuseeplrble organisms‘ including fungi. Patients should be carefully monitored during
`therapy, Ifsuperinfeciion occurs. appropriate measures should be taken. QT: Prolongation:
`yr 3 study involving healthy volunteers, doses of 7.5 and 15 mgfkg of v'IBATIV prolonged the
`on: interval, caution is warranted when prescribing VIBATIV to patients taking drugs known
`to prolong the QT interval. Patients With congenital long QT syndrome. known prolongation
`or the QTc interval. uncompensated heart failure. or severe left ventricular hypertrophywere
`not included in clinical trials of VIBATIV. Use of VIBATIV should be avoided in patients
`with these conditions. Coagulation Test
`interference: Although telavancin does not
`interfere with coagulation. it interfered with certain tests used to monitor coagulation. when
`conducted using samples drawn 0 lo til hours after VIBATIV administration for patients
`being treated once every 24 hours. Blood samples for these coagulation tests should be
`collected as close as possible prior to a patients next dose of VIBATIV. Blood samples
`for coagulation tests unaffected by VIBATIV may be collected at any time, No evidence
`or increased bleeding risk has been observed in clinical trials with VIBATIV. Teiavancin
`has no effect on platelet aggregation. Furthermore. no evidence of hypercoagulability has
`been seen. as healthy subjects receiving VIBATIV have normal levels of D—dimer and fibrin
`degradation products.
`
`trials. serious adverse events were
`the cSSSI clinical
`In
`ADVERSE REACTIONS:
`reported in Tit (69829) of patients treated wrth VIBATIV and most commenly included
`renal. respiratory. or cardiac events, Serious adverse events were reported in 5% (43r93lll
`or vancomycin-lreated patients. and most commonly Included cardiac.
`respiratory. or
`infectious events. Treatment discontinuations due to adverse events occurred in 3%
`[72929) of patients treated with VIBATIV. the most common events being nausea and rash
`[-196 each]. Treatment discnnlinuations due to adverse events occurred in 6% {53938)
`of vancomycin-lreated patients. the most common events being rash and pruritus {~1%
`each). The most common adverse cvenls occurring m‘ 210% of VlBATIV—treared patients
`were taste disturbance. nausea. vomiting. and loamy ""ne- The iOllWlng table displays the
`incidence of treatment-emergent adverse drug reactions reported in 22% of patients treated
`with VIBATIV pessiny related to the drug.
`
`
`
`
`
`VIBA‘I’IV
`
`
`
`
`
`
`
`
`
`
`
`Rigors
`
`Digestive System
`Nausea
`Vomiting
`
`
`
`Diarrhea
`
`
`Metabolic and Nutritional
`
`Decreased appetite
`Nervous System
`
`Vancom cin
`
`
`
`
`
`
`
`
`
`
`
`
`1 5%
`7%
`8%
`
`2%
`
` 3%
`
`4%
`
`27%
`14%
`7%
`
`3%
`
`
`
`
`
`Renal System
`
`
`“Described as a metallic or soapy taste.
`
`Increased Modality in Patients with HABPr
`WARNINGS AND PRECAUTIONS:
`VABP and Pro-existing Moderate to Severe Renal Impairment [Grill 550 lemin):
`in the analysis of patients (classified by the treatment received) in the two combined
`HABPNABP trials with pro-existing moderatelsevere renal
`impairment
`[CrCi 550 ml!
`min). all-cause mortality within 23 days of starting treatment was 95r24‘l {39%)
`In
`the vrcnnv group. compared with T3243 {30%)
`in the vancomycin group. All-cause
`modality at 28 days in patients without preexisting moderateisevere renal impairment
`[CrCl >50 lemin) was 86510 (17%) in the VIBATIV group and 93510 (13%) in the
`vanoomycin group. Therefore.
`\ran‘llvr use in patients with baseline CrCl 550 le
`min should be considered only when the anticipated benefit to the patient outweighs the
`potential risk. Decreased Clinical Response in Patients with cSSSI and Pro-existing
`ModeratelSevere Renal
`impairment (Grill 550 mUmin):
`In a subgroup anall’SlS of
`the combined cSSSI trials, clinical cure rates in the ViBATIV-treated patients were lower
`in patients with baseline CrCl 550 lemin compared with those with CrCl >50 "1U
`min. A decrease of this magnitude was not observed in vancomycln-treatedl Pailefils-
`Consider these data when selecting antibacterial therapy for use in patients wrlh c5351
`and with baseline moderatelsevere renal impairment. Nephrotoxicity: to DO!“ the HASH
`VABP trials and the cSSSI trials,
`renal adverse events were more likell' to 0001”. "1
`patients with baSElli'le cornorbidities known to predispose patients to ltldilelf dl'5lun?l‘°“
`(preexisting renal disease, diabetes mellitus. congestive heart failure. of hlpeilenstonl-
`The renal adverse event rates were also higher in patients who received concomitant
`medications known to affect kidney function reg. non-steroidal anti-inflammatory dlugs'
`ACE inhibitors. and loop diuretics}. Monitor renal funclion {i.e.. serum creatinine. creattnine
`clearance) in all patients receiving VlElATiV. Values should be obtained prior to Initiation
`of treatment, during treatment (at 43- to T2—hour intervals or more frequenfll’r ll Cl'fllciilll'
`indicated). and at the end of therapy. It renal function decreases. the benefit of ochhnurng
`VIBATIV versus discontinurng and initiating therapy with an alternative agent should be
`assessed. In patients with renal dysfunction. accumulation of the solubrlrzer hydroxypropyl-
`belacyclodexlrin can occur. Pregnant Women and Women of Childbearrng Potential:
`Avoid use ot'VIEATIV during pregnancy unless the potential benefit to the patient outweyghs
`the potential risk to the fetus. VIBATIV caused adverse developmental outcomes In 3
`animal species at clinically relevant doses. This raises concern about potential adverse
`developmental outcomes in humans. Women of childbearing potential should have a
`serum pregnancy test prior to administration of VIBATIV.
`If not already pregnant. women
`of childbearing potential should use effective contraception during VIEATI‘J treatment.
`Hypersensitivity Reactions: Serious and sometimes fatal hypersensitivity reactions.
`including anaphylaclic reactions. may occur after first or subsequent doses. Discontinue
`VIBATIV at first sign of skin rash. or any other Sign of hypersensitivity. Teiavancin is a
`semi-synthetic derivative of vancomycin:
`it is unknown if patients with hypersensitivity
`reactions to vancomycin will experience cross—reactivity to leiavancin. VIBATIV should be
`used with caution in patients with known hypersensitivity to vanoomycin. Intusion»ReIated
`Reactionsrv’lBATIV is a Iipoglycopeptide antibacterial agent and should be administered
`over a period of fill minutes to reduce the risk of infusion-related reactions. Rapid
`intravenous infusions of the glycopeptide class ofantimicrobial agents can cause “Red-man
`5yndrome'-like reactions including: flushing of the upper body, urticaria. pruritus. or rash.
`Stopping or slowing the infusion may result in cessation of these reactions. Closrrr'dium
`dwells-Associated Diarrhea: Cfosln'dr'um affiliate—associated diarrhea (CDAD) has been
`reported with nearly all antibacterial agents and may range in severity from mild diarrhea
`to fatal colitis. Treatment with antibacterial agents alters the fibre of the colon and may
`permit overgrowth or (2. criteria, C, dirnclle produces toxins A and B which contribute to
`the development of CDAD. Hypertoxin-produclng strains of C. didicile cause increased
`morbidity and morlality. since these infections can be refractory to antimicrobial therapy
`and may require colectomy. CDAD must be considered in all patients who present with
`Manufactured for:
`diarrhea following antibiotic use. Careful medical history is necessary because CDAD
`Theravance. Inc.
`has been reported to occur more than 2 months alter the administration of antibacterial
`South San Francisco. CA 94050
`agents.
`ll CDAD is suspected or confirmed. ongoing antibiotic use not directed against
`C. dirncr'lc may need to be discontinued. Appropriate fluid and electrolyte managmletdrialwasccnieo
`protein supplementation. antibiotic treatment or C. difficr’ie. and surgical evaluatiooohuuhr and magma August 2013
`Subject US Cr: pyright Law-5
`
`In HABPNABP clinical vials. serious adverse events were reported in at is or patients treated
`with UlElATlV and 26% of patients who received vancomycin.Treatment discontinuations
`due to adverse events occurred in 3% fbflfist) of patients who received VIBATIV, the most
`common events being acute renal failure and electrocardiogram QTc interval prolonged
`(4% each). Treatment disooniinuaiions due to adverse events occurred In 5% (40!?52) oi
`vancomycin-patients. the most common events being septic shock and mulli-organ failure
`(<i‘ltt. The following table displays the incidence of Irealment-emergent adverse drug
`reactions reported in 25% of HABPNAEIP patients treated with VIBATIV possibly related
`to the drug.
`
`\I'IBATIV
`{N=751)
`
`Vancomycin
`(N=752)
`
`
`
`
`5%
`
`
`4%
`Vomiting
`
`
` Renal Failure Acute 5%
`
`
`In the event of overdosage. vrsnrrv should be discontinued and
`DVERDOSAGE:
`supportive care is advised with maintenance of glomerular filtration and careful monitoring
`of renal function. The clearance of telavancin by continuous venovenous hernofiltratlurl
`tCWH] has not been evaluated in a clinical study,
`
`MK
`WK
`Theravance'
`
`Page 2 of 17
`
`

`

`
`
` AAC
`
`.1nurnezts.'\.‘5in.urg
`
`EDITOR IN CHIEF (2015)
`Louis 3. Rice
`Brown University, Providence: ill.
`
`EDITORS
`Paul G. Ambrose. Editor (2017]
`institute for ClmrcalPharmacodynamics,
`Lotham, MY.
`David R. Andes, Editor (2017)
`University ofWisconsin, Madison, Wis:
`Sevtap Arikan-Akdagli, Editor 12015}
`Hacettepe University Medical School,
`Ankara, Turkey
`Robert A. Bonomo, Editor (2016)
`Louis Stokes Cleveland VA Medical Center,
`Cleveland, Ohio
`Helen Boucher, Editor (2019)
`Tufts Medical Center. Boston, MA
`Henry F. Chambers, Editor (2019)
`San Francisco General Hospital
`San Francisco, Grill.
`Yohei Doi. Editor (2019)
`University ofPittsburgh School ofMedr'crnc.
`Pittsburgh, PA
`Robert L. LaFernina. Editor (2015)
`Sch wenksw'lte, Po.
`
`Wilbur K. Milhous. Editor (2017}
`University olSourh Florida,
`Tampa, Fla.
`Eric Nuermberg er, Editor (201171
`Johns i iopltr‘ns University
`Boltim ore, Md.
`David M. Shlaes, Editor (2015)
`Antl-lntectives Consulting,
`Stoninglon, Conn.
`-—________——
`
`Thomas E. Shank, Chairman, Journals
`Board
`
`Barbara M. Goldman, Director, Journals
`Noel Y. Lln, Production Editor
`Ellie Ghatineh. Assrstam Production Editor
`
`
`EDITORIAL BOARD
`Mark D. Adams (2015]
`Jeffrey D. Alder (20151
`Michael N. Alekshun {2014)
`Peter 1.. Anderson [20‘ 43
`Yoshtchlka Arakawa (20161
`Cesar A. Arias (2014}
`Michel Arthur (2014}
`Dale L. Barnard (2016)
`Adolf Bauernfeind (2014)
`Arnold S. Bayer (20161
`Jeffrey M. Becker {2014]
`Albert Berghuls 12:11 51
`Jonathan D. Herman (2015)
`Joseph 5. Berllno. Jr. (2014}
`SuJata M. Bhavnanl 120141
`Patrlcla Bradford {2015)
`Frederick S. Buckner [20161
`Jtirgen B. Bulitta (20141
`David M. Burger {20151
`Karen Bush (2016)
`Edmund V. Capparelll {20141
`Alessandra Carattoll (2015]
`Guy Carter (2014]
`W, LaJean Chaffin (2015:
`Joseph W. Chow {2014}
`Karl V. Clemons [2016]
`Joseph M. Colaclna (201:1:
`Marc S. Cullett (20151
`William Couet [20l41
`Manuel Cuenca—Estrella [20161
`Michael H. Cynamon (2016)
`T. M. E. Davis (2014)
`Charles R. Dean [20161
`Boudewijn de Jonge (20151
`Sunlta M. deSousa (20151
`Roberto Docarrlpn (20163
`Jean-Denls Docquler (2014i
`Curtis J. Donskey (2015]
`Thomas J. Daugherty (2014)
`Stephen Douthwalte (20:51
`Karl Drllca {20151
`Michael N. Dudley (2016}
`Paul M. Dunman (2015)
`Mira Edgeuon (2016)
`Christopher A. Elklns {2015)
`Evelyn EIlls-Grosse (2014]
`Andrea Endlmlanl (2016)
`Alan N. Engelman [2015}
`Paul D. Fey [20161
`Raina N. Flchorova (20151
`Davld A. Fldock (2016)
`Scott G. Filler [20151
`L. Mark Fisher (2014}
`Annette W. Fatherglll {2014}
`Jean-Marie Frére (20151
`Niels FtlmodteMeiler (20151
`Moreno Gallenl [2015)
`Dale N. Gerding {2015]
`Mahmoud Ghannoum (2016)
`Brian E. Gilbert (2016}
`Marek Gnladkowsltl (20161
`
`July 2014 - Volume 58 - Number 7
`
`Howard 5. Gold (2014]
`Maureen M. Goodenow (2014)
`Matthias Gene {2016}
`Elena Govorkova [20141
`M. Lindsay Grayson (2014]
`Larisa V. Gubareva E20151
`Paul Gubblns (20141
`Tawand'a Gumbo {2015)
`Johnny Ho {2014)
`Henry 5. Helm! Ill (2016]
`Paul S. Hoffman (2015)
`Stephen Hughes {201:1}
`Yasuyoshl lie (201:1)
`Frederick lmmermann {2014)
`Yoshlkazu lil'lll (2014]
`Tetuyo lta (2016]
`Susan E. Jensen (2015)
`James H. Jorgensen [2014]
`William R. Kirkpatrick (2015)
`Herbert A. Kirst (20141
`Thllo Kohler(20151
`Dlmltrlos Kontoylannls E20141
`Fred C. Krebs (20151
`Ba rry Krelswlnh (2016}
`Mark H. Krystal (201-11
`Joseph Kutl [20151
`Mar1e Therese Labro (20141
`Ebblng Lautenbach (20161
`James E. Leggett (2014}
`Russell E. Lewis (20141
`Catherlne Liu [2.015)
`Thomas Lodlse (20141
`Olga Lomovskaya [2014}
`Jose L. Lopez-Ribot {2014]
`Arnold Loule(20151
`Ala sdalr MacGowan {20151
`Luls Manlnez-Martlnez (2014:
`Paul M. Mchcholas (20:41
`Joseph Melelladls (2015]
`Steven Meshnlck 12GB)
`th MIrtagou {2014]
`John F. Mohr Ill (2015]
`Lawrence 1. Martin {2015)
`Roger L. Nation [2015)
`Charles H. Nightingale (201:1)
`Angela M. Nlllus [2016)
`Patrice Nordma no (2015]
`Eric Oldfield (2015)
`Antonio Oliver (2015)
`Luls Ostrosky~2elchner [20141
`Lucia Pallecchl (2016)
`Timothy G. Palzklll (201211
`Annallsa Pantostl {201.11
`Krlsztina Papp-Wallace (2016]
`Sally R. Partridge (20141
`Amy K. Patlck [21314]
`John R. Perfect (213141
`Michael A. Pfaller {2015)
`Johann Pltout (2014)
`Laurent Poltel [2015)
`John H. Powers [II {20151
`
`Steven J. Prnian (2315]
`Michael J. Putcl (2314}
`Anne Marie Queenan (20161
`Philip N. Rather (2015]
`Adrian 5. Ray (2314)
`Michael Robek (2014)
`Marilyn Roberts {2016}
`Keith A. Rodvold {20:5}
`Mary-Claire Roghmann (20161
`Phlllp J. Rosenthal (2014}
`Slddhanha Roychoudhury {2014)
`Christopher M. Rublno (20151
`Ethan Rubinstein (2016}
`Hello S. Sader [20151
`Nadya Sake moto (2016)
`George Sakoulas [20151
`Dominique Sanglard (20 I 51
`Maurizio Sanguinem [2016)
`Stefan Saraflanos (201 5]
`Stefan Schwarz (20141
`Alberto Severlnl {2016)
`William M. Shafer (2015)
`Lynn L. Silver [2014)
`Jared A. Silverman (2014i
`Shabblr Slmjee12014}
`Marlon J. Skalweit [20141
`James Spencer (2016)
`Judith Steenbergerl (2014)
`Usha Stlefel (20151
`Deanna A. Sutton [20141
`Gilda Tachedjlan (2015]
`Vincent H. Tarn [2015)
`Joel Taming (2015}
`Daniel J. Tenney (20161
`Fred C. Tenover £20151
`Ursula Theuretzbacher [20W
`Marcelo E, Tolmasky (2016)
`Paul M. Tulkens (2015}
`Leonidas S. Tzouvelekls (2016]
`Julia A. Urblna (20161
`Sergei Vakulenko [20151
`Pletro E. Varaldo (2014)
`Jonathan L. Vennerstrorn (20161
`Mark A. Wainberg [2014}
`Karl A. Wethovetz [2016)
`David G. White (2014)
`Nicholas J. White (2016}
`Richard J. Whitley {2014)
`Nathan P. Wlederhold (2016)
`Brian ngdahl (2014}
`Malcolm E. Winkler (2014]
`Gerard D. Wright (20161
`Jim 2. Wu {2016]
`Wlng Cheung Yarn l2014i
`5. Steve Van (2016;
`Michael Zasloff (201 :11
`E. Lynn Zechledrlch (2015}
`Steven L. Zelchner (2016]
`Helen I. Zgurskaya {20161
`George Ci. Zhanel (2014]
`
`Antimicrobial Agents and Chemotherapy (ISSN 0066-48041, an interdisciplinary publication of the American Society for Microbiology (ASM), 1752 N St. NW.
`Washington, DC 20036-2904, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial, antiviral, and antiparasitic agents and
`chemotherapy. Instructions to Authors can be Found at httpy‘rlournalitasasmprgrtf-‘issl9 and are updated throughout the year. Antimicrobial Agents
`and Chemotherapy is published monthly, one volume per year. institutional print subscription prices (per year) are: $1,213, U.S.,' $1,276, Canada; $1,305,
`Europe; $1,336, Latin America; $1,340, rest of world. Member print subscription prices (per year) are: 521?, U.S.; $231, Canada; 3294, Europe,- 5319,
`Latin America; $323, rest of world. Single copies are: $100, nonmember; $50, member {Canadians add 651 or HST Where applicablel- F01 prices 0f
`Electronic versions or for correspondence relating to subScriptions, defective copies, missing issues, and availability of back issues, contact the Sub-
`SUlFJtions Unit, ASM (asmioumalstelsubscriptionofficecoml. Correspondence relating to reprint orders should be directed to ASM Author Services
`lASM.AuthorServlcesSuppottfiscenveocomi, and correspondence relating to disposition of submitted manuscripts, proofs, and general editorial matters should
`be directed to the Journals Department, American Society for Microbiology, 1252 N St, NW. Washington, DC 20036-2904. Phone: 1202} 73773600 (see
`http:/r’journals.asm.orgr'site.lmiscrstalfcontactsxhtml].
`Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues;
`residents ofall other countries must submit claims within 6 months ofpubllcation of the issues. Claims for issues missing because oflailure to report an address
`change or for issues "missing From files" will not be allowed.
`Periodicals postage paid at Washington, DC 20036. and at additional mailing offices.
`POSTMASTEH: Send address changes to Antimicrobial Agents and Chemotherapy, ASM, 1152 N St., N.W., Washington, DC 20036-2904.
`CODEN: AMACCQ
`Made in the United States of America. Prlnted on acid-free paper.
`doi:10.l128!AAC.masthead.58-7
`Copyright (r: 2014, American Society for Microbiology. All Rights Reserved.
`The Code at the bottom of the first page of an article in this journal indicates the copyright owner’s consent that copies of the article may be made for
`personal use or for personal use of specific clients, This consent is given on the condition, however, that the copier pay the stated per-copy fee through the
`Copyright Clearance Center, Inc. 222 Rosewood Drive. Danvets, MA 01923, for copying beyond that permitted by Sections 10? and 108 of the U5. Copyright
`Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes. for creating
`new collective works, or for resale.
`
`Page 3 of 17
`
`

`

`
`
`AAC
`Jam ::;
`
`TABLE OF CONTENTS
`
`EDITORIAL
`
`In Memoriam: Robert C. Muellering. Jr.
`
`MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS
`
`Bactericidal Activity of the Human Skin Fatty Acid H's-6-
`Hexadecanoic Acid on Staphylococcus aureris
`
`Copper Complexation Screen Reveals Compounds with Potent
`Antibiotic Properties against Methicillin-Resistant
`Staphylococcus our-arts
`
`The Broad-Spectrum Antiviral Compound ST-669 Restricts
`Chlamydia! Inclusion Development and Bacterial Growth and
`Localizes to Host Cell Lipid Droplets within Treated Cells
`
`Structural Changes and Differentially Expressed Genes in
`Psertdomonas aeruginosa Exposed to MeropenermCiprolloxaiSin
`Combination
`
`Effects of Renal Impairment on the Pharmacokinetics of
`Morinidazole: Uptake Transporter-Mediated Renal Clearance of
`the Conjugated Metabolites
`
`MECHANISMS OF RESISTANCE
`
`Positions and Numbers of PICS Mutations in Candida albicans
`Selectively Influence In Vitro and In Vivo Susceptibilities 10
`Echinocantlin Treatment
`
`Selection of Drug Resistance—Mediating Plasmodium falciparum
`Genetic Polymorphisms by Seasonal Malaria Chemopreventlfln
`in Burkina Faso
`
`IncHiType Plasmid Harboring blam‘qus: Nauru-r: and ‘1’"34
`Genes Recovered from Animal Isolates
`
`[SIR-Mediated Plasticity of IncLi'M Plasmids Leads to the
`Insertion of blaoxmqs into the Escherichia coli Chromosome
`
`The meat Homolog mecC Confers Resistance against B-Lactams
`in Staphylococcus mrmus Irrespective of the Genetic Strain
`Background
`
`JULY 2014 0 VOLUME 53 a N0. 7
`
`Louis B. Rice, George M. Eiiopoulos,
`George A. Jacoby
`
`358343534
`
`Michael L. Cartron, Simon It. England,
`Alina Iulia Chiriac. Michaela Iosten,
`Robert Turner, Yvon ne Rainer,
`Alexander Hurd, Hans-Georg Sahl.
`Simon lones, Simon 1. Foster
`
`Mehri Haeili, Casey Moore,
`Christopher]. C. Davis, James B.
`Cochran, Santosh Shah, ch B.
`Shrestha, You fang Zhang, Stefan ll.
`Bossmann, William H. Benjamin, Olaf
`Kutsch, Frank Wolschendorf
`
`Kelsi M. Sandoz, William (3. Valiant.
`Steven G. Eriksen, Dennis E. Hruby,
`Robert D. Allen 11], Daniel D. Rockey
`
`Vera Locia Dias Siqueira, Rosilene
`Fressntti Cardoso, Katiany Rizxicri
`Calcffierrracioii. Regiane Bertin de
`Lima Scodro, Maria Aparecida
`Fernandez, Adriana Fiorini, 'i‘ania
`Ueda-Nakamura, Benedito Prado Dias-
`Filho, Celso Vataru Nakamura
`
`Kan Zho ng, Xiuli Li, Ccn Xie, Yifiln
`Zhang, Dafang Zheng, Xiaoyan Chen
`
`M. lackncr, M. 'l‘scherner, M. Schaller,
`K. Kuchler, C. Mair, 1i. Sartori, F. lstel,
`M. C. Arendrup, C. loss—Flor]
`
`Anyirékun iiabrice Some. Issaka Zongo,
`Yves-Daniel Conipaoré. Souleymanc
`Sakandé, Francois Nosten, lean-Bosco
`Ouédraogo, Philip J. Rosemhnl
`
`Andreas Schliiter, Patrice Nordmann,
`Romy A. Bonnin, Yves Millemann,
`Felix G. Eikmeyer, Daniel Wibberg,
`Alfred I’iihler, Laurent Poirel
`
`R. Beyrouthy, F. Robin, I. Delmas, L_
`Gll‘fllld, G. Dalmasso, F. Dabbo ussi, M.
`Hamzé, It. Bonnet
`
`Britta liallhausen, André Kricgeskorte,
`Nina Schleimer, Georg Peters, Karsten
`Becker
`
`3599-3609
`
`3727—3736
`
`3860 #38 66
`
`395 7—3967
`
`415374161
`
`3626—3635
`
`3660 —3 665
`
`3768—37?3
`
`37'85—3790
`
`3791—3798
`
`Instructions to Authors are available at http:/ljaurnnlitasasm.orgltMéSlEJ.
`
`Continued on following page
`
`Page 4 of 17
`
`

`

`Continuedfmm Precedifigp‘age
`
`JULY 2014 - VOLUME 53 - NUMBER 7
`
`Lack of Antimicrobial Bactericidal Activity in Mycobacrerium
`abscessus
`
`Metabolic Compensation of Fitness Costs Associated with
`Overexpression of the Multidrug Efflux Pump MexEF-OprN in
`Pseudomonas aerugirtosa
`
`Crystal Structure of Max-I, a Unique Plasmid-Mediated Class C
`B-Lactamase with Hydroly'tic Activity towards Moxalactam
`
`A Low—Affinity Penicillin-Binding Protein 2x Variant Is
`Required for Heteroresistnnce in Streptococcus pneumoniac
`
`Sheltering Effect and Indirect Pathogenesis of Carbapenem-
`Resistant Aciuetobacter baummmii in Polymicrobial Infection
`
`Putrescine Reduces Antibiotic-Induced Oxidative Stress as a
`Mechanism of Modulation of Antibiotic Resistance in
`Burkhoideria cenoceprtcia
`
`Complete Nucleotide Sequence of Two Multidrug-Resistant
`IncR Plasmids from Kiebsiellrt pneumoniae
`
`Plasmid Carriage of Mam)”, in Clinical Aeinetobacter
`baummmh’ Isolates from India
`
`Florian P. Maurer, Vera L. Bruderer,
`Claudia Ritter, Claudio Casteiberg,
`Guido V. Bloemberg, Erik C. Bottger
`
`Jorge Olivares, Carolina Alvarez?
`Ortega, Jose Luis Martinez
`
`Takuma Oguri, Takamitsu Furuyama,
`Takashi Okuno, Yoshikazu isiiii,
`Kuzuhiro Tateda, Robert A. Bonomo,
`Akiko Shimizu-lbuka.
`
`Hansjiirg Engel, Moana Mika. Dalia
`Denapaite, Regine llakenbeck, Kathi-in
`Mijlllemann, Manfred lleller, Lucy J.
`Hathaway, Markus Hilty
`
`Yu-Ting Ling, shu_chen Km, yiffzu
`Lee, Chien-Pei Chen, Shu—Wen Lin,
`Li-Jiuan Shem, Chang-Phone Fung,
`Wenr Long Cho, 'l‘e- Li Chen
`
`3828 —3836
`
`3904—3913
`
`3914—3920
`
`3934 4:941
`
`3933_3999
`
`Omar M. El-Halfawy, Miguel A.
`Valvano
`
`4162-4171
`
`Fabrice Compain, Lionel Frangeul,
`Laurence Drieux, Charlotte Verdet,
`Sylvain Brisse, Guillaume Arlet,
`Dominique Decré
`
`Lim S. Jones, Mark A. Tolcman, Janis L.
`Weeks, Robin A. Howe, Timothy R.
`Walsh, Karthikeyan K. Kumarasamy
`
`4207—4210
`
`4211—4213
`
`4219—4221
`
`4230 —4233
`
`4238—4241
`
`3708 —5713
`
`3757—3761
`
`3814 —381 9
`
`3921—3926
`
`Phasevarions Mediate Epigenetic Regulation 0f Antimicrobial
`Susceptibility in Net'sserirz meningitrdis
`
`Freda E.-C. Jen, Kate L. Seib. Michael P.
`Jennings
`
`Phase-Va;-iable Expression of hurt Modulates the Resistance of
`Neisseria gonorrhoeac to Cationic Antimicrobial Peptides
`
`Inhibition of Aminoglycoside 6'-N—Acetyltransferase Type lb by
`zinc; Reversal of Amikacin Resistance in Acinetoboctcr
`baumamiii and Escherichia coli by a Zinc Ionophore
`SUSCEPTIBILITY
`
`Justin L. Kandler, Sandeep J. Joseph,
`Jacqueline T. Balthazar, Vijaya
`Dhulipala, Timothy D. Read, Ann E.
`Jcrse, William M. Shafer
`
`David L. Lin, Tung Tran, Jamal Y.
`Alain, Steven R. Herron, Maria Soledad
`Ramirez, Marcelo E. Tolmasky
`
`Amikacin-Fosfomycin at a Five-to-Two Ratio: Characterization
`of Mutation Rates in Microbial Strains Causing Ventilator
`Associated Pneumonia and Interactions with Commonly Used
`Antibiotics
`
`A. Bruce Montgomery, Paul R.
`thomberg, Tammy Abuan, Kathie—
`Anne Walters, Robert K. Flamm
`
`Unacceptably High Error Rates in Vital-t 2 Testing of Cefepime
`Susceptibility in Extendad-Spectrum-B-Lactamase—Producing
`Escherichia coli
`
`Antifungal Sttsceptibilities of Candida Isolates Causing
`Bloodstream Infections at a Medical Center in Taiwan,
`2009-2010
`
`Validation ofAntibiotic Susceptibility Testing Guidelines in a
`Routine Clinical Microbiology Laboratory Exemplifies General
`Key Challenges in Setting Clinical Breakpoints
`
`Nathaniel J. Rhodes, Chad L.
`Richardson, Ryan Heraty, Jiajun Liu,
`Michael Malczynski, Chan Qi, Marc H.
`Scheth
`
`Yu—Tsung Huang, ChiaeYing Liu,
`Chun—Hsing Liao, Kuei—Pin Chung,
`Wang-Huei Sheng, Po—Ren I-Isneh
`
`Michael Hombach, Patrice Courvalin,
`Erik C. Bottgcr
`
`This materialwas copied
`at the NLM and may be
`Subiect US Cnntrrizht Laws
`
`Continued airfoiiowing page
`
`Page 5 of 17
`
`

`

`Contilmedfrnm preceding page
`
`JULY 2014 v VOLUME 58 -
`
`NUMBER 7
`
`In Vivo Assessment of Drug Efficacy against Mycobacterium
`abscesses Using the Embryonic Zebrafish Test System
`
`4~Amino Bis—Pyridinium Derivatives as Novel Antileishmanial
`Agents
`
`In Vitro Amphotericin B Susceptibility of Matassezia
`pothydernmtis Determined by the CLSI Broth Microdilution
`Method and Etest Using Lipid-Enriched Media
`
`In Vitro Activity of AZD5847 against Geographieaily Diverse
`Clinical Isolates of Mycobactcrium tuberculosis
`
`Anti-Candida Activity of Fluoxetine Alone and Combined with
`Fluconazole: a Smergistic Action against Fluconazole-Resistant
`Strains
`
`ANTIV IRAL AGENTS
`
`Audrey Bern ut, Vincent l.c Moigne,
`Tiffany Lesne, Georges Lutfalla, Jean~
`Louis Herrmann, Laurent Kremer
`
`Veronica Gomez-Perez, José Ignacio
`Manzano, Raquel Garcia-l—Iernandez,
`Santiago Castanys, Joaquin M. Campos
`Rosa, Francisco Gamnrro
`
`Sergio Alvarez-Perez, Jesé 1.. Blanco,
`Teresa Peléez, Maite Cntuli, Maria E.
`Garcia
`
`Jim Werngren, Maria Wijkander,
`Nasrin Perskvist. V. Balasubramunian,
`Vasan K. Sambandamurthy, Camilla
`Rodrigues, Sven Hoffner
`
`Ana S. Oliveira, Carlos A. Gaspar, Rita
`Palmeira-de—Oliveiru, Jose Martina:
`de~Olivcira, Ana Palmeira—tlc—Olivcira
`
`Significance and Clinical Management of Persistent Low—Level
`Viremia and Very-Low-Level Viremia in HIV-l-lnfected
`Patients
`
`Patrick Ryscavage, Sean Kelly. Jon athan
`7.. Li, P. Richard I-larrigan, Babafcmi
`Taiwo
`
`Efficiency of Incorporation and Chain Termination Determines
`the Inhibition Potency of 2'-Modified Nucleotide Analogs
`against Hepatitis C Virus Polymerase
`
`Amy Fung, Zhinan Jin. Natalia
`Dyalkina, Guangyi Wang, Leo
`Beigelman, Jerome Deval
`
`A Conserved Hydrogen-Bonding Network of [’2 bis-
`Tctrahydrofuran-Containing HIV—1 Protease Inhibitors (PIS)
`with a Protease Active-Site Amino Acid Backbone Aids in Their
`Activity against PI-Resistant HIV
`
`Akt Inhibitor MK2206 Prevents Influenza leNl Virus
`Infection In Vitro
`
`Pharmacokinetics-Pharmacodynamics of the I-Ielicase-l’rimase
`Inhibitor Pritelivir following Treatment of Wild—Type or
`Pritelivir—Resistant Virus Infection in a Murine Herpes Simplex
`Virus 1 Infection Model
`
`Characterization of a Respiratory Syncytial Virus L Protein
`Inhibitor
`
`Enhanced Antiretroviral Therapy in Rhesus Macaques Improves
`RT-SHIV Viral Decay Kinetics
`
`Ravikiran S. Yedidi, I—Iarisha Garimella,
`Manabu Aolci, Hiromi Aoki-Ogata,
`Darshan V. Desai, Simon B. Chang,
`David A. Davis, W. Sean Iiyvie. Joshua
`D. Kaufman, David W. Smith,
`Debananda Das, Paul T. Wingficld,
`Kenji Maeda, Arun K. Ghosh, l-Iiroaki
`Mitsuya
`
`Oxana V. Denisova, Sandra Sédcrholm.
`Salla Virtanen, Carina Von Schantz,
`Dmitrii Bychkov, [Elena Vashchinkina,
`Jens Desloovere, Janne 'I'yneli, Nllna
`lkonen, Linda L. 'I‘heisen, ’l‘uula A.
`Nyman, Sampsa Matikainen, Olli
`Kallioniemi, Ilkka Julkuncn, Claude I’.
`Muller, Xavier Szlclcns, Vladislav V.
`Verkhusho, Denis E. Kainov
`
`Subhajit Biswas, Soumi Sukla, Thomas
`Goldner, Hugh J. Field, Dirk Kropeit,
`Daniela Paulsen, André Welbers, Helga
`Ruebsomen —Schaeff, Holger
`Zimmermann, Alexander Birkmann
`
`ChoiALai ’I‘iong-Yip, Lisa
`Aschenbrenner, Kenneth D. Johnson,
`Robert E. McLaughlin, Jun Fan,
`SrceRupa Challa, Hui Xiong, Qin Yu
`
`Thomas W. North. Andradi Villalobos,
`Selwyn J. Hurwitz, Jesse D. Deere,
`Joanne Higgins, Payel Chatterjee, Sijia
`Tao, Robert C. Kauffman, Paul A.
`Luciw, James J. Kohler, Raymond F.
`Schinazi
`
`4054—4063
`
`4103—4112
`
`4203-4206
`
`4222—4223
`
`4224 —4226
`
`3585—6598
`
`3636 “3645
`
`367973688
`
`3689-6696
`
`3843—3852.
`
`3867—3873
`
`3927—3933
`
`This materiaiwas copied
`
`Continued on following page
`
`Page 6 of 17
`
`

`

`Continued from preceding page
`
`JULY 2014 - VOLUME 58 - NUMBER 7
`
`Intracellular Antiviral Activity of Low-Dose Ritonavir in
`Boosted Protease Inhibitor Regimens
`
`Inhibition of Foamy Virus Reverse Transcriptase by Human
`Immunodeficiency Virus Type 1 RNase H Inhibitors
`
`EPIDEMIOLOGY AND SURVEILLANCE
`
`Polymorphisms in medrl, Pfcrt, and anhcl Genes Are
`Associated with Reduced In Vitro Activities of Quinine in
`Plasmodimn falciparum Isolates from Western Kenya
`
`Emergence of Clinical Salmonella enterica Serovar
`Typhirnurium Isolates with Concurrent Resistance to
`Ciprofloxacin, Ceftriaxone, and Azithromycin
`
`Characteristics of Escherichia coli Sequence Type 131 Isolates
`That Produce Extended-Spectrum B-Lactamases: Global
`Distribution of the H30~Rx Sublineage
`
`The T2 Mycobrtcterium tuberculosis Genotype. Predominant in
`Kampala, Uganda, Shows Negative Correlation with
`Antituberculosis Drug Resistance
`
`Inhibitor-Resistant TEM- and OXA-l-Producing Escherichia
`calf Isolates Resistant to Amoxicillin-Clavulanate Are More
`Clonal and Possess Lower Virulence Gene Content than
`Susceptible Clinical Isolates
`
`Amedeo De Nicole, Marco Simiele,
`Andrea Calcagno, Adrian Mohamed
`Abdi, Stefano Bottom, Giovanni Di
`Perri, Antonio D’Avolio
`
`Angela Corona, Anna Schneider,
`Kristian Schweimer, Paul Rosch,
`Birgitta M. Wohrl, limo Tramontano
`
`Jelagat Cheruiyot. Luicer A. Ingasia,
`Angela A. Omondi, Dennis W. lama,
`Benjamin Ii. Opot, Joseph M. Ndegwa,
`Joan Mativo, Agnes C. Cheruiyot.
`Redemptah Yeda, Charles Okudo.
`Peninah Muiruri, Ngalah S. Bidii,
`Lorna]. Chebon, Paul O. Angienda,
`Fredrick 1.. Eyase, Jacob D. Johnson.
`Wallace D. Bulimo, Ben Andagaiu,
`Iloseah M. Akala, Edwin Kamau
`
`Marcus Ho Yin Wong, Meiying Yan,
`Edward Wai Chi Chan, Kan Biao,
`Sheng Chen
`
`Gisele Peirano, Akke K. van der Bij,
`Joshua 1.. Freeman, Laurent Poirel,
`Patrice Nordmann, Michael Costello,
`Veronika L. Tchesnokova, Johann
`D. D. Pitout
`
`Dcus Lukoye, Fred A. Katabazi,
`Kenneth Musisi, David P. Kateete,
`Benon B. Asiimwe, Moses Okee, Moses
`L. loloba, Frank G. J. Cobelens
`
`Jesus Oreo, Juan Jose Gonzalez-Lopez,
`Adriana